Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older
diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment.
This objective of this study is to determine whether three eight-hour long sessions of
MDMA-assisted psychotherapy, scheduled three to five weeks apart, can be safely administered
to participants with PTSD, and whether combining a fully therapeutic dose of MDMA with
psychotherapy, when compared with a low ("active placebo") dose of MDMA, will reduce PTSD
symptoms. Participants will be randomly assigned to receive the full dose of MDMA (125 mg) or
assigned to receive a low or "active placebo" dose of MDMA (25 mg) during each of three
experimental sessions.
Phase:
Phase 2
Details
Lead Sponsor:
Multidisciplinary Association for Psychedelic Studies